NASDAQ$NDSN
Nordson Corporation · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Nordson's Q3 2023 performance saw decreased sales but strong profitability amidst demand weakness in electronics and biopharma, with strategic focus on Ascend strategy and growth framework execution.
Nordson Corporation reported a 2% decrease in sales to $649 million for the third quarter of fiscal year 2023, with a net income of $128 million, or $2.22 per share. Despite the sales dip, the company maintained strong profitability with an EBITDA of $208 million, representing 32% of sales. The team remains focused on the execution of our Ascend strategy to achieve top tier growth with leading margins and returns.
- Sales decreased by 2% to $649 million due to organic decline in electronics and biopharma markets.
- EBITDA remained strong at $208 million, representing 32% of sales.
- Earnings per share were $2.22, while adjusted earnings per share were $2.35.
- The company is narrowing its full-year revenue growth guidance to 0% to 2% and adjusted earnings per share to $8.90 to $9.05.
Headline financials
Revenue & EPS history
Nordson · Revenue · Quarterly
$649M
Revenue by segment
Nordson · $649M total across 3 segments · Q3 2023
- Industrial Precision Solutions$338M-0.8%52.1%
- Medical and Fluid Solutions$171M—26.3%
- Advanced Technology Solutions$140M-56.5%21.5%
Forward guidance
The Company is narrowing its previously issued full-year revenue growth guidance to 0% to 2% over record fiscal 2022 and adjusted earnings guidance to the range of $8.90 to $9.05.
Tailwinds
- Backlog remains strong at $890 million, heavily weighted toward systems and medical interventional solutions.
- Order entry has been steady throughout the quarter.
- Fourth quarter sales are expected to be the strongest of the year, increasing low-mid single digits over the prior year.
- The acquisition of the ARAG Group is forecasted to add approximately $20-$30 million of sales.
- Focus on Ascend strategy to achieve top tier growth with leading margins and returns.
Headwinds
- Revenue growth guidance narrowed to 0% to 2%.
- Demand weakness persists in electronics and biopharma end markets.
- Organic sales decrease was driven by ongoing pressure in electronics, primarily semiconductor dispense applications, and biopharma end markets.
- Adjusted earnings guidance narrowed to the range of $8.90 to $9.05.
- Increased interest expense and lower operating profit.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2023
+0.3%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-0.5%
Avg return
30 days after
54%
37 / 69 earnings
Positive
+15.8%
Q4 2017
Best reaction
-14.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.8% | — | — | |
| Q1 2026 | -1.7% | -1.5% | -12.2% | |
| Q4 2025 | -0.3% | +0.0% | +10.5% | |
| Q3 2025 | +2.9% | +6.0% | +5.4% | |
| Q2 2025 | +6.8% | +8.5% | +9.9% | |
| Q1 2025 | +0.3% | -1.3% | -6.4% | |
| Q4 2024 | -9.4% | -11.4% | -20.9% | |
| Q3 2024 | +6.9% | +7.4% | +6.7% | |
| Q2 2024 | -10.5% | -12.4% | -14.5% | |
| Q1 2024 | +3.5% | +2.6% | +1.7% | |
| Q4 2023 | +5.1% | +7.1% | +5.8% | |
| Q3 2023 | +1.5% | +2.7% | -2.0% | |
| Q2 2023 | +1.1% | +1.7% | +8.8% | |
| Q1 2023 | -13.9% | -10.5% | -15.6% | |
| Q4 2022 | +1.5% | -2.1% | +2.3% | |
| Q3 2022 | -2.1% | -4.7% | -10.4% | |
| Q2 2022 | +2.7% | +7.1% | -3.8% | |
| Q1 2022 | -3.5% | -0.9% | -1.1% | |
| Q4 2021 | -5.9% | -7.2% | -9.9% | |
| Q3 2021 | +2.2% | +3.4% | +4.0% | |
| Q2 2021 | +7.4% | +9.8% | +8.0% | |
| Q1 2021 | -0.0% | +2.4% | +6.3% | |
| Q4 2020 | -2.9% | -0.5% | +1.2% | |
| Q3 2020 | -7.1% | -8.5% | -6.6% | |
| Q2 2020 | +1.7% | +1.0% | +12.4% | |
| Q1 2020 | -0.3% | -4.6% | -37.9% | |
| Q4 2019 | -1.6% | -0.5% | -1.2% | |
| Q3 2019 | -3.0% | -4.6% | +5.9% | |
| Q2 2019 | -1.0% | -5.4% | -1.6% | |
| Q1 2019 | -3.0% | -0.5% | -8.1% | |
| Q4 2018 | +7.7% | +3.7% | +10.9% | |
| Q3 2018 | -0.9% | +0.7% | +7.1% | |
| Q2 2018 | -4.2% | -5.5% | -3.3% | |
| Q1 2018 | -2.0% | -1.3% | -3.9% | |
| Q4 2017 | +15.8% | +14.5% | +19.5% | |
| Q3 2017 | -10.2% | -12.3% | -5.3% | |
| Q2 2017 | -5.9% | -7.6% | -8.2% | |
| Q1 2017 | +0.1% | +0.5% | +2.0% | |
| Q4 2016 | +5.2% | +7.2% | +7.0% | |
| Q3 2016 | +10.6% | +8.0% | +7.1% | |
| Q2 2016 | +15.7% | +16.8% | +12.2% | |
| Q1 2016 | +9.1% | — | — | |
| Q4 2015 | -8.1% | — | — | |
| Q3 2015 | -14.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +0.0% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | +0.8% | — | — | |
| Q2 2014 | +9.2% | — | — | |
| Q1 2014 | +2.0% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q3 2013 | +0.1% | — | — | |
| Q2 2013 | -7.4% | — | — | |
| Q1 2013 | -9.8% | — | — | |
| Q4 2012 | -1.4% | — | — | |
| Q3 2012 | +10.6% | — | — | |
| Q2 2012 | +10.5% | — | — | |
| Q1 2012 | +5.0% | — | — | |
| Q4 2011 | -1.9% | — | — | |
| Q3 2011 | -3.0% | — | — | |
| Q2 2011 | -1.1% | — | — | |
| Q1 2010 | +1.5% | — | — | |
| Q1 2011 | +3.3% | — | — | |
| Q2 2010 | +2.1% | — | — | |
| Q4 2010 | +2.1% | — | — | |
| Q4 2008 | +2.1% | — | — | |
| Q4 2009 | +0.2% | — | — | |
| Q3 2009 | +0.2% | — | — | |
| Q3 2010 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro